Umberto Malapelle
Overview
Explore the profile of Umberto Malapelle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
299
Citations
3537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malapelle U, Chen C, de Alava E, Hofman P, Kazdal D, Kim T, et al.
J Pathol Clin Res
. 2025 Mar;
11(2):e70018.
PMID: 40052485
Current European/US guidelines recommend that molecular testing in advanced non-small cell lung cancer (aNSCLC) be performed using next-generation sequencing (NGS). However, the global uptake of NGS is limited, largely owing...
2.
Marchetti C, Ergasti R, Capomacchia F, Giannarelli D, Mastrantoni L, Pepe F, et al.
Gynecol Oncol
. 2025 Mar;
195:16-25.
PMID: 40048982
Objective: Selecting the maintenance strategy for advanced tubo-ovarian high-grade serous carcinoma (HGSC) is challenging. This study evaluates the correlation among chemotherapy response score (CRS), homologous recombination deficiency (HRD) status, and...
3.
4.
Scimone C, Pepe F, Russo G, Palumbo L, Ball G, Morel P, et al.
J Liq Biopsy
. 2025 Mar;
3:100133.
PMID: 40026570
Introduction: p.G12C hot spot mutations has rapidly modified diagnostic algorithm for lung cancer patients electing Non-Small Cell Lung Cancer (NSCLC) patients to target treatment. As regards, patients that harbor this...
5.
Montalti R, Pepe F, Cassese G, Russo G, Malapelle U, Carlomagno C, et al.
Eur J Surg Oncol
. 2025 Feb;
51(6):109706.
PMID: 40009912
Introduction: Liver resection represents the cornerstone treatment for Colo-Rectal Liver Metastases (CRLM), but it is still followed by a high recurrence rate. The identification of a valid and reproducible predictor...
6.
Fusco N, Malapelle U
Crit Rev Oncol Hematol
. 2025 Feb;
207:104626.
PMID: 39909182
Molecular alterations in the Phosphoinositide 3-kinase (PI3K) pathway are key drivers of tumorigenesis and progression in hormone receptor-positive, HER2-negative (HR+/HER2 -) metastatic breast cancer (MBC). These genomic changes are actionable...
7.
Petrillo A, Ottaviano M, Pompella L, Giunta E, Pisapia P, Marte G, et al.
Ther Adv Med Oncol
. 2025 Jan;
17:17588359241255628.
PMID: 39867743
Gastric cancer (GC), one of the tumours with the highest mortality worldwide, is not a homogeneous disease, showing different features according to location, macroscopic aspect, histotype and molecular alterations. Adenocarcinoma...
8.
Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L, et al.
JCO Glob Oncol
. 2025 Jan;
11():e2400416.
PMID: 39847746
Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only...
9.
Fusco N, Jantus-Lewintre E, Serrano M, Gandara D, Malapelle U, Rolfo C
Crit Rev Oncol Hematol
. 2025 Jan;
104619.
PMID: 39824370
Liquid biopsy (LB) has revolutionized molecular pathology, offering non-invasive insights into tumor biology. However, widespread adoption is hindered by a lack of standardized protocols, requiring robust quality control and harmonized...
10.
Gristina V, Bazan V, Barraco N, Taverna S, Manno M, Raccosta S, et al.
Mol Oncol
. 2025 Jan;
PMID: 39780749
Extracellular vesicle (EV) monitoring can complement clinical assessment of cancer response. In this study, patients with advanced non-small cell lung cancer (NSCLC) undergoing osimertinib, alectinib, pembrolizumab or platinum-based chemotherapy ± ...